Risk factors and treatment outcomes of bloodstream infection caused by extended-spectrum cephalosporin-resistant Enterobacter species in adults with cancer

Diagnostic Microbiology and Infectious Disease

Volumn 78, Issue 2, 2014, Pages 172-177

  Huh, Kyungmin ^a   Kang, Cheol In ^a   Kim, Jungok ^a   Cho, Sun Young ^a   Ha, Young Eun ^a   Joo, Eun Jeong ^a   Chung, Doo Ryeon ^a   Lee, Nam Yong ^a   Peck, Kyong Ran ^a   Song, Jae Hoon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Bacteremia; Cephalosporin resistance; Enterobacter; Risk factor; Treatment outcome

Indexed keywords

CARBAPENEM; CEPHALOSPORIN; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOODSTREAM INFECTION; CANCER GROWTH; CANCER PATIENT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENTEROBACTER AEROGENES; ENTEROBACTERIACEAE INFECTION; FEMALE; HUMAN; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; RETROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK; SURGERY; TREATMENT FAILURE; TREATMENT OUTCOME;

BACTEREMIA; CEPHALOSPORIN RESISTANCE; ENTEROBACTER; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CEPHALOSPORIN RESISTANCE; ENTEROBACTER; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84892485461     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.11.002     Document Type: Article

References (19)

1. American Thoracic Society, Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
2. Bouza E., Garcia de la Torre M., Erice A., Loza E., Diaz-Borrego J.M., Buzon L. Enterobacter bacteremia. An analysis of 50 episodes. Arch Intern Med 1985, 145:1024-1027.
3. Chow J.W., Fine M.J., Shlaes D.M., Quinn J.P., Hooper D.C., Johnson M.P., et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991, 115:585-590.
4. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement (M100-S20) 2010, June 2010 Update: CLSI, Wayne, PA.
5. Deal E.N., Micek S.T., Ritchie D.J., Reichley R.M., Dunne W.M., Kollef M.H. Predictors of in-hospital mortality for bloodstream infections caused by Enterobacter species or Citrobacter freundii. Pharmacotherapy 2007, 27:191-199.
6. Flynn D.M., Weinstein R.A., Nathan C., Gaston M.A., Kabins S.A. Patients' endogenous flora as the source of "nosocomial" Enterobacter in cardiac surgery. J Infect Dis 1987, 156:363-368.
7. Freifeld A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52:e56-e93.
8. Heinze G., Schemper M. A solution to the problem of separation in logistic regression. Stat Med 2002, 21:2409-2419.
9. Hidron A.I., Edwards J.R., Patel J., Horan T.C., Sievert D.M., Pollock D.A., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011.
10. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Oh M.D., et al. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome. Clin Infect Dis 2004, 39:812-818.
11. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Kim E.C., et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005, 49:760-766.
12. Lin Y.C., Chen T.L., Ju H.L., Chen H.S., Wang F.D., Yu K.W., et al. Clinical characteristics and risk factors for attributable mortality in Enterobacter cloacae bacteremia. J Microbiol Immunol Infect 2006, 39:67-72.
13. Marcos M., Inurrieta A., Soriano A., Martinez J.A., Almela M., Marco F., et al. Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia. J Antimicrob Chemother 2008, 62:397-403.
14. O'Neal C.S., O'Neal H.R., Daniels T.L., Talbot T.R. Treatment outcomes in patients with third-generation cephalosporin-resistant Enterobacter bacteremia. Scand J Infect Dis 2012, 44:726-732.
15. Paterson D.L., Ko W.C., Von Gottberg A., Mohapatra S., Casellas J.M., Goossens H., et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004, 39:31-37.
16. Son J.S., Song J.H., Ko K.S., Yeom J.S., Ki H.K., Kim S.W., et al. Bloodstream infections and clinical significance of healthcare-associated bacteremia: a multicenter surveillance study in Korean hospitals. J Korean Med Sci 2010, 25:992-998.
17. Song E.H., Park K.H., Jang E.Y., Lee E.J., Chong Y.P., Cho O.H., et al. Comparison of the clinical and microbiologic characteristics of patients with Enterobacter cloacae and Enterobacter aerogenes bacteremia: a prospective observation study. Diagn Microbiol Infect Dis 2010, 66:436-440.
18. Watanakunakorn C., Weber J. Enterobacter bacteremia: a review of 58 episodes. Scand J Infect Dis 1989, 21:1-8.
19. Ye Y., Li J.B., Ye D.Q., Jiang Z.J. Enterobacter bacteremia: clinical features, risk factors for multiresistance and mortality in a Chinese university hospital. Infection 2006, 34:252-257.